Lv41
728 积分 2024-03-05 加入
Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
7天前
已完结
Antibody–drug conjugates come of age in oncology
8天前
已完结
Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
8天前
已完结
Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody–Drug Conjugates
8天前
已完结
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio
13天前
已完结
Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics
13天前
已完结
Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody–Drug Conjugate Exposure in Solid Tumor
14天前
已完结
Met, metastasis, motility and more
15天前
已完结
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
1个月前
已完结
Chemical technology principles for selective bioconjugation of proteins and antibodies
1个月前
已完结
Ailanthone inhibits non-small cell lung cancer growth and metastasis through targeting UPF1/GAS5/ULK1 signaling pathway
皖公网安备34019202002308
